NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss of $0.10

NRx Pharmaceuticals (NRXP) Provides Business Update, Reports Q2, Focuses on Reactivation & Advancement of Psychiatry Franchise

August 15, 2022 6:55 AM EDT

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the second quarter of 2022 and provided a business and clinical update.

"During our second quarter, we reactivated clinical development in our psychiatry franchise around our lead compound, NRX-101. NRX-101 has been awarded Breakthrough Therapy designation and a Special Protocol Agreement for severe bipolar depression with acute suicidal ideation and behavior (ASIB) by the U.S. Food and Drug Administration (FDA), said Stephen Willard, Chief Executive Officer of the Company. "We anticipate... More